Principal investigator | Title |
Margaret S. Shatara, MD | PNOC029: Nivolumab and DAY101 for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults |
Mohamed Abdelbaki, MD | Phase 1 Trial of Engineered HSV G207 in Children with Recurrent or Refractory Cerebellar Brain Tumors |
Andrew Cluster, MD | ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study |
Mohamed Abdelbaki, MD | Replication Repair Deficiency Biobank (RRD) |
Dan Willis, MD | ACCL2031: A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors |
Andrew Cluster, MD | Targeting pediatric brain tumors with sodium glucose cotransporter 2 inhibitors (SGLT2i) |
Andrew Cluster, MD | A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features |
Andrew Cluster, MD | A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) |
Andrew Cluster, MD | A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) |
Andrew Cluster, MD | A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
Robert J. Hayashi, MD | A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051) |
Robert J. Hayashi, MD | The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study |
Robert J. Hayashi, MD | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol APEC1621SC, APEC1621A, APEC1621D, APEC1621F, APEC1621K, APEC1621M, APEC1621N |
Mohamed S. Abdelbaki, MD | A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling |
Andrew Cluster, MD | HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue |
Robert J. Hayashi, MD | Classification of Acute Lymphoblastic Leukemia Consent for Collection of Additional Bone Marrow and Consent for Study Entry and Shipment of Samples |
Shalini Shenoy, MD | PEPN22P1: A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods |
Mohamed S. Abdelbaki, MD | FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors |
Margaret S. Shatara, MD | A Pilot Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma |
Allison King, MD, MPH, PhD | Symptom Screening Linked to Care Pathways for Children With Cancer: a Cluster Randomized Trial |
Andrew Cluster, MD | A Prospective Multi-Institutional Study to Assess the Risk of Radiation Induced Vasculopathy and Stroke as well as Stroke Recurrence in Children with Cancer who Received Radiation Therapy to the Neck and/or Brain |
Andrew Cluster, MD | A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations |
Amy Armstrong, MD | A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1 |
Andrew Cluster, MD | A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) |
Andrew Cluster, MD | A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression |
Mohamed S. Abdelbaki, MD | A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor |
Margaret S. Shatara, MD | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors |
Joshua Rubin, MD, PhD | A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma |
Andrew Cluster, MD | Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG |
Andrew Cluster, MD | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma |
Andrew Cluster, MD | Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma |
Margaret S. Shatara, MD | CA209-908 – Phase Ib/II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies |
Mohamed S. Abdelbaki, MD | PNOC 001 – Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children |
Margaret S. Shatara, MD | A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors |
Mohamed S. Abdelbaki, MD | PNOC013 – A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma |
Andrew Cluster, MD | Phase I-II Study of MEK162 for Children with Ras/Raf Pathway Activated Tumors |
Andrew Cluster, MD | Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT |
Stephanie M. Perkins, MD | Cognitive Biomarkers in Pediatric Brain Tumor Patients |
Frederick S. Huang, MD | ANBL1531: Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma |
Andrew Cluster, MD | Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas |
Mohamed S. Abdelbaki, MD | REGN2810 in Pediatric Patients with Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed or Recurrent Glioma |